Akeso (HKSE:09926) Research & Development: HK$1,838 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09926 Akeso Inc HKSE:09926
55 GF Score
Price HK$96.20
GF Value HK$131.29
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Akeso Research & Development?

Akeso HKSE:09926 +0.21% 55 Research & Development is HK$1,838 Mil as of Jun. 2026. GuruFocus rates HKSE:09926 with a GF Score™ of 55/100 and a GF Value™ of HK$131.29 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Akeso's Research & Development for the six months ended in Jun. 2026 was HK$906 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was HK$1,838 Mil.

Akeso  (HKSE:09926) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Akeso Research & Development Related Terms

Akeso Research & Development Historical Data

* Premium members only.

The historical data trend for Akeso's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso Research & Development Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 1,375.02 1,477.52 1,371.62 1,268.06 1,740.00

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 639.89 633.45 799.28 932.19 906.09
HKSE:09926
55GF Score
Akeso Inc HKSE:09926
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akeso Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,838 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$1,838 Mil mean?
Akeso (HKSE:09926) has a Research & Development of HK$1,838 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Akeso and its competitors.
Is Akeso's Research & Development too high?
Akeso's current Research & Development is HK$1,838 Mil. Overall, Akeso has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akeso's Research & Development compare to VRTX and REGN?
Akeso's Research & Development of HK$1,838 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Akeso and its competitors. Akeso's current Research & Development is HK$1,838 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (HKSE:09926) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$131.29, compared to a current price of HK$96.20 — trading 26.7% below its estimated fair value. The current Research & Development is HK$1,838 Mil. Akeso's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Akeso (HKSE:09926), the current Research & Development is HK$1,838 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akeso (HKSE:09926) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of HK$96.20 is trading 26.7% below its estimated GF Value™ of HK$131.29. GuruFocus considers Akeso to be Modestly Undervalued.

Key valuation signals for HKSE:09926:

  • Research & Development: HK$1,838 Mil
  • GF Value™: HK$131.29 vs. price of HK$96.20 (26.7% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the HKSE:09926 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akeso Business Description

Other Exchanges AKESF:USA4RY:Germany
Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
55GF Score

Get the complete analysis for HKSE:09926

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$96.20
Price
HK$131.29
GF Value